NorthRock Partners LLC Has $1.41 Million Position in Vertex Pharmaceuticals Incorporated $VRTX

NorthRock Partners LLC reduced its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.0% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,176 shares of the pharmaceutical company’s stock after selling 98 shares during the period. NorthRock Partners LLC’s holdings in Vertex Pharmaceuticals were worth $1,414,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of VRTX. Brighton Jones LLC boosted its position in shares of Vertex Pharmaceuticals by 15.0% during the fourth quarter. Brighton Jones LLC now owns 4,427 shares of the pharmaceutical company’s stock worth $1,783,000 after buying an additional 579 shares during the period. GAMMA Investing LLC boosted its position in shares of Vertex Pharmaceuticals by 25.1% during the first quarter. GAMMA Investing LLC now owns 5,002 shares of the pharmaceutical company’s stock worth $2,425,000 after buying an additional 1,005 shares during the period. Opal Wealth Advisors LLC acquired a new position in shares of Vertex Pharmaceuticals during the first quarter worth about $82,000. Dynamic Advisor Solutions LLC acquired a new position in Vertex Pharmaceuticals during the first quarter valued at approximately $1,353,000. Finally, Ritholtz Wealth Management boosted its position in Vertex Pharmaceuticals by 14.2% during the first quarter. Ritholtz Wealth Management now owns 3,459 shares of the pharmaceutical company’s stock valued at $1,677,000 after purchasing an additional 430 shares during the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on VRTX shares. Raymond James Financial started coverage on Vertex Pharmaceuticals in a research report on Tuesday, September 2nd. They set a “market perform” rating for the company. Stifel Nicolaus reduced their price target on Vertex Pharmaceuticals from $494.00 to $455.00 and set a “hold” rating for the company in a research report on Tuesday, August 5th. BMO Capital Markets set a $530.00 price target on Vertex Pharmaceuticals and gave the company an “outperform” rating in a research report on Tuesday, August 5th. Leerink Partnrs raised Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 25th. Finally, Evercore ISI reduced their price target on Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a research report on Thursday, September 11th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have assigned a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $494.38.

Vertex Pharmaceuticals Stock Down 0.1%

NASDAQ:VRTX opened at $407.37 on Tuesday. The stock’s 50 day moving average price is $392.61 and its two-hundred day moving average price is $438.14. The firm has a market capitalization of $104.45 billion, a price-to-earnings ratio of 29.12 and a beta of 0.43. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Monday, August 4th. The pharmaceutical company reported $4.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.24 by $0.28. The firm had revenue of $2.94 billion for the quarter, compared to analyst estimates of $2.90 billion. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The business’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($12.83) earnings per share. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Insider Buying and Selling at Vertex Pharmaceuticals

In other news, Director Bruce I. Sachs bought 5,000 shares of the stock in a transaction dated Wednesday, August 6th. The shares were bought at an average price of $389.68 per share, for a total transaction of $1,948,400.00. Following the completion of the purchase, the director owned 45,000 shares in the company, valued at approximately $17,535,600. This trade represents a 12.50% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.